Developer docs
API playgroundTry for free, no card

Search company profiles

Artis Ventures

Full company profile

uuid000024i

Namestring
Artis Ventures
Legal namestring
Artis Ventures
Websiteurl
av.co
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Artis Ventures is a private venture capital firm founded in 2001 and headquartered at 499 Jackson Street in San Francisco. The firm invests at the intersection of technology and life sciences (its "TechBio" thesis), backing early-stage companies across AI-driven healthcare, biotech platforms, medical devices, digital health, and microbiome science. With 11-50 employees and a small partner group led by Founder and Managing General Partner Stuart Peterson, Managing Partner Vasudev Bailey, and Partner Omair Khan, the firm combines a 25-year track record with deep scientific judgment sourced through its Fellows Program (PhDs, MDs, and postdocs) and its AI Health Alliance of leading hospital systems.

The firm's "products" are its portfolio companies, each operating independently: Rad AI (generative AI radiology serving one-third of US health systems and 9 of 10 largest US radiology practices), Seed Health (microbiome science, Target's fastest-growing probiotics brand at 500%+ revenue growth over three years), Conceivable Life Sciences (AI-powered automated IVF platform that produced the first fully automated ICSI birth), ONTO Health (incubated fertility/longevity provider), Metriport (open universal API for patient medical data), Science (medical device/consumer electronics blending, founded by Neuralink co-founder Max Hodak), Luminate (at-home cancer infusion, expanding to 40 partner oncology clinics), Unnatural Products (macrocyclic peptide therapeutics with a Novartis license worth up to $1.7B in milestones), and Cartography Biosciences (antibody-based cancer therapies, backed in part by Pfizer Ventures). Historical exits include YouTube (acquired by Google in 2006), Stemcentrx (acquired by AbbVie in 2016), and Palantir (IPO in 2020).

The business model is venture capital returns: the firm deploys capital into early-stage equity rounds, leads or co-leads financings, and earns returns through IPOs, acquisitions, and secondary transactions when portfolio companies exit. Revenue is not publicly disclosed. Deal sourcing flows through direct founder outreach, the Fellows Program, the AI Health Alliance, and the firm's community of pharma executives, biotech founders, investors, and regulators. Notable 2024-2026 activity includes participation or co-lead roles in financing rounds totaling over $200M across multiple portfolio companies.

Short descriptiontext

Artis Ventures is a San Francisco-based venture capital firm founded in 2001 that invests in early-stage TechBio companies at the intersection of technology and life sciences, backing founders in AI-driven healthcare, biotech, medical devices, and microbiome science through capital, clinical network access, and a Fellows Program.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital funding, techbio equity investing, healthcare startup investment, biotech venture capital, early stage technology investment
Industry1 code
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
NAICS code1 code
  • All Other Financial Investment Activities52399
SIC code1 code
  • Investors, Nec6799
Product category
Technology Venture Capital
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Returns
TypeLicensing Royalties
Description

ARTIS generates returns through equity ownership in portfolio companies. Returns are realized through IPOs, acquisitions, and secondary transactions when portfolio companies exit. Notable exits include YouTube (acquired by Google), Stemcentrx (acquired by AbbVie), and Palantir (IPO).

av.co
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1TechBio
Description

ARTIS's investment thesis focusing on the convergence of computer science and life science at the intersection of technology and biology.

av.co
+2 more records
Core offering1 text field

Artis Ventures is a venture capital firm that invests equity capital in early-stage companies at the intersection of technology and life sciences (TechBio). It provides portfolio companies with capital investment, strategic partnership, operational support, and access to a curated network of hospital systems (AI Health Alliance), pharma executives, and scientific talent through the Fellows Program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Multiple successful exits including YouTube ($1.65B Google acquisition 2006), Stemcentrx (AbbVie acquisition), and Palantir (IPO 2020)
+1 more record
Product overview1 text field

Artis Ventures is a venture capital firm that does not offer a unified product or platform. Instead, it provides venture capital funding, strategic partnership, and operational support to visionary founders building companies at the intersection of technology and life sciences (TechBio). The firm's portfolio consists of distinct portfolio company brands spanning healthcare AI, data platforms, microbiome science, fertility technology, oncology, and consumer health. These portfolio companies operate independently and each offers its own distinct products and services.

Product and service1 record
1Venture Capital Investment
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

OncoAssure, a portfolio-related company, signed research collaboration with Mount Sinai's Icahn School of Medicine in New York to validate its prostate cancer test. Illustrates ARTIS network connections with leading academic medical centers.

2AI Health Alliance (Hospital Network)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

AI Health Alliance is a curated network of leading hospital systems partnering with ARTIS to shape the future of healthcare innovation. The network connects portfolio companies with healthcare systems for pilot programs, clinical validation, and market access.

av.co
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

TechBio-focused VC investing aggressively at the intersection of AI and healthcare/biotech. Directly comparable to ARTIS—Khosla even led Rad AI's $50M Series B in which ARTIS participated—making it the closest head-to-head peer for both deal flow and growth-stage rounds.

TypeDirect peer
Description

Frontier-tech and science VC investing in 'bold, sciencеe- and technology-driven' companies across AI, biology, and healthcare. Directly comparable to ARTIS's TechBio thesis with a similar specialization in transformative, high-conviction bets.

TypeDirect peer
Description

Large generalist firm with a dedicated Bio + Health fund investing across digital health, biotech, and AI × biology. Comparable to ARTIS in thesis area but with substantially more capital and broader sector coverage.

TypeDirect peer
Description

Deep-tech VC with an explicit computational biology practice (DCVC Bio). Directly comparable to ARTIS for AI/biology convergence bets and competing for similar early-stage TechBio deal flow.

TypeDirect peer
Description

Long-tenured biotech and frontier-science investor backing companies from inception through commercialization. Comparable to ARTIS in life-sciences orientation, though ARCH leans earlier-stage and biotech-dominant versus ARTIS's AI/bio hybrid.

TypeDirect peer
Description

Venture firm founded by Bill Maris specifically focused on health tech, biotech, and AI-driven medicine. Closely comparable to ARTIS in sector focus and stage, competing for similar healthcare AI founders.

TypeBroad incumbent
Description

Large, established tech VC with a frontier-tech thesis. Less specialized in TechBio than ARTIS but overlapping in tech/biology frontier bets; ARTIS was an early investor in Founders Fund-backed Palantir, illustrating historical overlap.

TypeEmerging player
Description

Tech-focused firm building companies at the frontier of AI, logistics, and bio. Comparable to ARTIS in frontier-thesis orientation and portfolio-construction style, though with a wider tech remit beyond healthcare.

TypeEmerging player
Description

Mission-driven VC backing founders addressing world-scale problems in health, sustainability, and technology. Partially overlapping with ARTIS in health/longevity bets (e.g., portfolio overlaps with Seed Health-adjacent consumer health themes).

10Allen & Company
TypeOthers
Description

Private investment bank and venture investor with historic exposure to media, tech, and science-enabled companies. Adjacent rather than directly competitive, but historically a peer for visionary founders in tech/biology frontier plays.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment173 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Artis Ventures

Technology Venture Capitalav.co

Artis Ventures is a San Francisco-based venture capital firm founded in 2001 that invests in early-stage TechBio companies at the intersection of technology and life sciences, backing founders in AI-driven healthcare, biotech, medical devices, and microbiome science through capital, clinical network access, and a Fellows Program.

What Artis Ventures does

Artis Ventures is a private venture capital firm founded in 2001 and headquartered at 499 Jackson Street in San Francisco. The firm invests at the intersection of technology and life sciences (its "TechBio" thesis), backing early-stage companies across AI-driven healthcare, biotech platforms, medical devices, digital health, and microbiome science. With 11-50 employees and a small partner group led by Founder and Managing General Partner Stuart Peterson, Managing Partner Vasudev Bailey, and Partner Omair Khan, the firm combines a 25-year track record with deep scientific judgment sourced through its Fellows Program (PhDs, MDs, and postdocs) and its AI Health Alliance of leading hospital systems.

The firm's "products" are its portfolio companies, each operating independently: Rad AI (generative AI radiology serving one-third of US health systems and 9 of 10 largest US radiology practices), Seed Health (microbiome science, Target's fastest-growing probiotics brand at 500%+ revenue growth over three years), Conceivable Life Sciences (AI-powered automated IVF platform that produced the first fully automated ICSI birth), ONTO Health (incubated fertility/longevity provider), Metriport (open universal API for patient medical data), Science (medical device/consumer electronics blending, founded by Neuralink co-founder Max Hodak), Luminate (at-home cancer infusion, expanding to 40 partner oncology clinics), Unnatural Products (macrocyclic peptide therapeutics with a Novartis license worth up to $1.7B in milestones), and Cartography Biosciences (antibody-based cancer therapies, backed in part by Pfizer Ventures). Historical exits include YouTube (acquired by Google in 2006), Stemcentrx (acquired by AbbVie in 2016), and Palantir (IPO in 2020).

The business model is venture capital returns: the firm deploys capital into early-stage equity rounds, leads or co-leads financings, and earns returns through IPOs, acquisitions, and secondary transactions when portfolio companies exit. Revenue is not publicly disclosed. Deal sourcing flows through direct founder outreach, the Fellows Program, the AI Health Alliance, and the firm's community of pharma executives, biotech founders, investors, and regulators. Notable 2024-2026 activity includes participation or co-lead roles in financing rounds totaling over $200M across multiple portfolio companies.

Artis Ventures firmographics

Firmographics
Name
Artis Ventures
Legal name
Artis Ventures
Website
https://av.co
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
11–50 employees
Short description
Artis Ventures is a San Francisco-based venture capital firm founded in 2001 that invests in early-stage TechBio companies at the intersection of technology and life sciences, backing founders in AI-driven healthcare, biotech, medical devices, and microbiome science through capital, clinical network access, and a Fellows Program.
Ownership category
akta.pro rank

Artis Ventures industry classification

Industry
Product category
Technology Venture Capital
NAICS
All Other Financial Investment Activities (52399)
SIC
Investors, Nec (6799)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity

Keywords

  • Venture capital funding
  • Techbio equity investing
  • Healthcare startup investment
  • Biotech venture capital
  • Early stage technology investment

Where Artis Ventures is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Artis Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Venture Capital Returns: ARTIS generates returns through equity ownership in portfolio companies. Returns are realized through IPOs, acquisitions, and secondary transactions when portfolio companies exit. Notable exits include YouTube (acquired by Google), Stemcentrx (acquired by AbbVie), and Palantir (IPO).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Artis Ventures product offering

Product offering

Core offering

Artis Ventures is a venture capital firm that invests equity capital in early-stage companies at the intersection of technology and life sciences (TechBio). It provides portfolio companies with capital investment, strategic partnership, operational support, and access to a curated network of hospital systems (AI Health Alliance), pharma executives, and scientific talent through the Fellows Program.

Product overview

Artis Ventures is a venture capital firm that does not offer a unified product or platform. Instead, it provides venture capital funding, strategic partnership, and operational support to visionary founders building companies at the intersection of technology and life sciences (TechBio). The firm's portfolio consists of distinct portfolio company brands spanning healthcare AI, data platforms, microbiome science, fertility technology, oncology, and consumer health. These portfolio companies operate independently and each offers its own distinct products and services.

Differentiator

Problem solved

Functional benefit

Brands

  • TechBio: ARTIS's investment thesis focusing on the convergence of computer science and life science at the intersection of technology and biology.
  • ARTIS Fellows Program
  • ARTIS AI Health Alliance

Products and services

  • Venture Capital Investment

Quantifiable outcome

  • Multiple successful exits including YouTube ($1.65B Google acquisition 2006), Stemcentrx (AbbVie acquisition), and Palantir (IPO 2020)
  • +1 more outcomes

Companies that use Artis Ventures

Customer profile

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Artis Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Artis Ventures partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered supporting and core.

  • Mount Sinai Icahn School of MedicinesupportingStrategic or Co-development Partner · 7 January 2026OncoAssure, a portfolio-related company, signed research collaboration with Mount Sinai's Icahn School of Medicine in New York to validate its prostate cancer test. Illustrates ARTIS network connections with leading academic medical centers.
  • AI Health Alliance (Hospital Network)coreStrategic or Co-development Partner · 1 January 2024AI Health Alliance is a curated network of leading hospital systems partnering with ARTIS to shape the future of healthcare innovation. The network connects portfolio companies with healthcare systems for pilot programs, clinical validation, and market access.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Artis Ventures competitors and assessment

Company assessment

Direct peers

  • Khosla Ventures: TechBio-focused VC investing aggressively at the intersection of AI and healthcare/biotech. Directly comparable to ARTIS—Khosla even led Rad AI's $50M Series B in which ARTIS participated—making it the closest head-to-head peer for both deal flow and growth-stage rounds.
  • Lux Capital: Frontier-tech and science VC investing in 'bold, sciencеe- and technology-driven' companies across AI, biology, and healthcare. Directly comparable to ARTIS's TechBio thesis with a similar specialization in transformative, high-conviction bets.
  • Andreessen Horowitz (a16z Bio): Large generalist firm with a dedicated Bio + Health fund investing across digital health, biotech, and AI × biology. Comparable to ARTIS in thesis area but with substantially more capital and broader sector coverage.
  • DCVC (DCVC Bio): Deep-tech VC with an explicit computational biology practice (DCVC Bio). Directly comparable to ARTIS for AI/biology convergence bets and competing for similar early-stage TechBio deal flow.
  • ARCH Venture Partners: Long-tenured biotech and frontier-science investor backing companies from inception through commercialization. Comparable to ARTIS in life-sciences orientation, though ARCH leans earlier-stage and biotech-dominant versus ARTIS's AI/bio hybrid.
  • Section 32: Venture firm founded by Bill Maris specifically focused on health tech, biotech, and AI-driven medicine. Closely comparable to ARTIS in sector focus and stage, competing for similar healthcare AI founders.

Broad incumbents

  • Founders Fund: Large, established tech VC with a frontier-tech thesis. Less specialized in TechBio than ARTIS but overlapping in tech/biology frontier bets; ARTIS was an early investor in Founders Fund-backed Palantir, illustrating historical overlap.

Emerging players

  • 8VC: Tech-focused firm building companies at the frontier of AI, logistics, and bio. Comparable to ARTIS in frontier-thesis orientation and portfolio-construction style, though with a wider tech remit beyond healthcare.
  • Obvious Ventures: Mission-driven VC backing founders addressing world-scale problems in health, sustainability, and technology. Partially overlapping with ARTIS in health/longevity bets (e.g., portfolio overlaps with Seed Health-adjacent consumer health themes).

Others

  • Allen & Company: Private investment bank and venture investor with historic exposure to media, tech, and science-enabled companies. Adjacent rather than directly competitive, but historically a peer for visionary founders in tech/biology frontier plays.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Artis Ventures social profiles

Digital presence

Artis Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Artis Ventures leadership team

Management profile

Number of profiles

Profiles7 records

Artis Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Artis Ventures M&A and investment

M&A and investment

M&A

Investments173 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artis Ventures

What does Artis Ventures do?

Artis Ventures is a venture capital firm that invests equity capital in early-stage companies at the intersection of technology and life sciences (TechBio). It provides portfolio companies with capital investment, strategic partnership, operational support, and access to a curated network of hospital systems (AI Health Alliance), pharma executives, and scientific talent through the Fellows Program.

Is Artis Ventures a public or private company?

Artis Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Artis Ventures founded?

Artis Ventures was founded in 2001. It employs 11 to 50 people.

Where is Artis Ventures based?

Artis Ventures is headquartered in San Francisco, United States, in the North America region.

How does Artis Ventures make money?

One revenue line is on record: venture Capital Returns.

Who are Artis Ventures's main competitors?

Direct peers on record are Khosla Ventures, Lux Capital, Andreessen Horowitz (a16z Bio), DCVC (DCVC Bio), ARCH Venture Partners and Section 32. Founders Fund is listed as a broad incumbent. Emerging players are 8VC and Obvious Ventures. Allen & Company is listed as an others.

Does Artis Ventures have an API?

No public API is recorded for Artis Ventures.

What industry is Artis Ventures in?

Artis Ventures's product category is Technology Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 52399 and its SIC code is 6799.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Thebridge分散した患者記録を整理するMetriport、2,600万ドル調達Metriport raised $26 million in funding led by Matrix's TJ Parker, bringing its total to $28.4 million. The company's open-source platform organizes patient records from multiple medical institutions into a unified FHIR model. It plans to expand the platform and enhance AI, machine learning, and AI agent features.SiliconANGLEArkenstone Defense launches with $35M to help startups sell to the Pentagon - SiliconANGLEFederal contracting software startup Arkenstone Defense Inc. formally launched with $35 million in seed funding to provide a managed platform handling the compliance, security and workforce setup that startups need to enter the federal defense market. The company, founded by former Second Front Systems co-founder Peter Dixon and defense innovation veteran William Treseder, addresses a shrinking vendor base as the number of businesses willing to sell to the Pentagon dropped from 76,700 in 2017 to roughly 60,000 in 2021. The funding round was led by J2 Ventures with participation from Susa Ventures, Granite Hill Capital Partners and Artis Ventures.Pulse 2.0Arkenstone Defense Raises $35 Million Seed To Help Commercial Companies Enter Federal MarketArkenstone Defense emerged from stealth with $35 million in seed funding led by J2 Ventures, with participation from Susa Ventures, Granite Hill Capital Partners, and Artis Ventures. The company is building a managed platform that combines workforce operations, HR, payroll, insurance, personnel security, contracting support, compliance, and accreditation to help commercial technology companies navigate federal contracting requirements. The platform addresses operational barriers, such as CMMC Level 2 certification and cleared workforce standards, that prevent startups from accessing the Pentagon's acquisition spending of more than $300 billion annually.VentureburnArkenstone Defense Raises $35M to Simplify Government ContractingArkenstone Defense has raised $35 million in seed funding led by J2 Ventures, with participation from Susa Ventures, Granite Hill Capital Partners and Artis Ventures, to simplify government contracting for commercial technology companies. The Menlo Park-based startup offers a platform combining workforce management, compliance, payroll, personnel security and accreditation to help companies meet Pentagon procurement requirements including Cybersecurity Maturity Model Certification. More than two dozen defence technology companies already use the platform, and the funding will support expansion as annual Pentagon acquisition spending approaches $300 billion.FinSMEsArkenstone Defense Raises $35M in Seed FundingArkenstone Defense, a Menlo Park-based company developing an operating system for government contracting and compliance, raised $35 million in seed funding. The round was led by J2 Ventures with participation from Susa Ventures, Granite Hill Capital Partners, and Artis Ventures. The company's platform helps commercial companies meet the full operating requirements of selling to the U.S. government, including cleared workforce, payroll, personnel security, accreditation, and audit.The SaaS NewsArkenstone Defense Raises $35M SeedArkenstone Defense, a Menlo Park-based GovTech startup, raised $35 million in seed funding to develop a platform enabling commercial technology companies to navigate federal procurement and compliance. The round was led by J2 Ventures with participation from Susa Ventures, Granite Hill Capital Partners, and Artis Ventures. The company, founded by Peter Dixon and William Treseder, will use the capital to scale its managed platform that integrates workforce operations, HR, payroll, security, and accreditation services for firms seeking to sell to the U.S. government.VC News DailyArkenstone Defense Launches With $35MArkenstone Defense emerged from stealth with $35 million in seed funding to build an operating system for government contracting compliance, enabling commercial technology companies to meet requirements for cleared workforce, personnel security, and accreditation. The round was led by J2 Ventures with participation from Susa Ventures, Granite Hill Capital Partners, and Artis Ventures. The company aims to widen the commercial defense industrial base and help the United States field capability affordably and at scale.Venture Capital Access OnlineArkenstone Defense Launches with $35M to Help Commercial Companies Enter the Federal MarketArkenstone Defense emerged from stealth with $35M in seed funding led by J2 Ventures to provide a GovCon back office for commercial companies. The platform handles compliance, security, and accreditation, aiming to help firms enter the federal market. The company has over two dozen defense technology clients on its platform.VentureBeatArkenstone Defense Launches with $35M to Help Commercial Companies Enter the Federal MarketArkenstone Defense emerged from stealth with $35 million in seed funding led by J2 Ventures. The company provides a GovCon-native platform for commercial technology companies to handle government contracting compliance, including CMMC certification and cleared workforce. The platform aims to help more commercial innovators enter the U.S. federal defense market.Venture Capital Access OnlineAI-Enabled Fertility Care and Longevity Provider ONTO Health Closes $20 Million Series funded by ARTIS and HumaniaONTO Health closed a $20 million Series A round led by ARTIS and Humania. The funding will expand U.S. clinical operations and support expansion into the Gulf Cooperation Council region. The company combines AI-driven diagnostics with physician-led fertility care.